We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Study Highlights Low Sensitivity of Current Lyme Tests in Early Infection

By LabMedica International staff writers
Posted on 28 Apr 2026

Accurate laboratory diagnosis of early Lyme disease remains challenging because serologic responses may be limited soon after infection. More...

Missed detection at this stage can delay evaluation and management and complicate epidemiologic assessment. Clinical laboratories commonly employ standard or modified two-tiered testing algorithms to assess serum from suspected cases. A new study shows these approaches demonstrate low sensitivity in early infection, despite high specificity.

Researchers at the Lyme Disease Biobank in Portland, Oregon, evaluated standard two-tiered testing (STTT) and modified two-tiered testing (MTTT) algorithms in early Lyme disease. These two-tiered serologic workflows were applied to serum, and all configurations assessed were U.S. Food and Drug Administration (FDA)-cleared. The analysis compared four STTT or MTTT algorithms and assessed agreement among methods.

The study used serum from 107 cases of early Lyme disease, 69 of whom also provided a convalescent draw, alongside 144 endemic controls. Performance was evaluated at the initial blood draw and, where available, at convalescence. The investigators also examined algorithm concordance across samples.

Algorithm sensitivity at the initial blood draw ranged from 22% to 36%, while specificity ranged from 98% to 100%. MTTT approaches showed higher sensitivity than STTT overall, with no sensitivity difference observed between the two MTTT algorithms. One STTT algorithm was less sensitive than the other. Discordance was notable: among 45 laboratory-confirmed cases, only 22 were positive across all algorithms tested. In participants with a suspected erythema migrans lesion, the likelihood of a positive two-tiered result increased with longer lesion duration and when one or more constitutional symptom was present.

Findings were published online April 21, 2026, in the Journal of Clinical Microbiology. The work involved the Lyme Disease Biobank and collaborators. The results underscore limitations of current two-tiered diagnostics in early infection and point to a need for improved medical education on test interpretation.


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Automatic CLIA Analyzer
Shine i6000
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.